Stocks · News reference
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme" or the "Company") today announced that it has expanded its global collaboration and license agreement with argenx to develop and commercialize
Filed: 2026-09-30 AccNo: 0001159036-26-000128 Size: 170 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Halozyme Therapeutics shares rose 3.3% to $115.13 on strong volume, driven by investor optimism around its ENHANZE drug-delivery technology collaborations with major pharmaceutical companies. The company is expected to report quarterly earnings of $2.25 per share (+30.8% YoY) and revenues of $470.95 million (+32.9% YoY). With a 2.6% upward revision in consensus EPS estimates over the past 30 days and a Zacks Rank #2 (Buy) rating, analysts suggest monitoring the stock for potential continued strength.
Tempus AI expands its collaboration with Moderna and Merck to support sample collection and NGS services for intismeran autogene and Keytruda.
Morgan Stanley analyst Terence Flynn maintains Merck & Co (NYSE:MRK) with a Overweight and lowers the price target from $179 to $177.